Author Archives: admin


The woman who spent 7 years in and out of hospital battling rare condition some doctors had never seen – Leicestershire Live

When Allison Shatford was diagnosed with aplastic anemia in 1984 she was given just a 20 per cent chance of survival.

Before her diagnosis, the now 58-year-old described having headaches, bruising, prolonged periods and lethargy.

Eventually it became too much and she was taken to the Leicester Royal Infirmary (LRI) when she was just 23-years-old.

That's when she was given her diagnosis, two years after she first noticed that something might be wrong.

She spent seven years in and out of hospital before doctors gave her another shot at life.

Now, 28 years since her life-saving procedure Alison has written a book about the "frightening" experience.

"I can remember when I was in Florida with my friend and I could not stop bleeding, it was traumatic and that was two years before I was taken into hospital," she said.

"My bone marrow had completely shut down, it didn't make any red blood cells, plasma or oxygen.

"For the next seven years from the age of 23 I was dependant on the blood and platelet donors three times a week for seven years.

"As a young person at 23 my life was taken by this, but I fought it, I never wanted to die."

In her book she said that doctors told her she was only the 13th person to be diagnosed with aplastic anemia after she underwent a series of bone marrow tests.

Aplastic anemia is a serious condition that affects the blood and can happen suddenly.

It is also called bone marrow failure.

Essentially, the condition means that the bone marrow and stem cells don't produce enough blood cells.

There are three types of blood cell: red, white and platelets.

Red blood cells carry a protein called haemoglobin which carry oxygen around the body.

White blood cells help to fight bacterial infections and viruses.

Platelets help blood to clot.

There are multiple symptoms of aplastic anemia, they are: Fatigue, shortness of breath, rapid or irregular heart rate, pale skin, frequent or prolonged infections, unexplained bruising, nosebleeds and bleeding gums, prolonged bleeding from cuts, rashes, dizziness and headaches.

The condition is normally found withing children and adults over the age of 60.

According to the NHS the best form of treatment is a bone marrow transplant - without treatment the condition can be fatal.

Alison had hormone procedures in order to treat the condition, and she said that doctors at the LRI told her they had never seen anything like it.

She said that from 1984 to 1991 she was constantly in and out of the LRI as well as Hammersmith Hospital in London who were helping with treatment.

"I had a hormone procedure mainly used for aplastic anemia and that made me so much more poorly, I was desperate.

"Six months later I had the second course, the treatment involved hormones from horses and rabbits.

"Everyone would bring me carrots, lettuce and apples," she laughed.

"One week before my 30th birthday the doctors said 'Alison it doesn't look good.'

"Leukemia cells had been laying dormant now they had woken up - I had aplastic anemia and luekemia."

She said the medical professionals said that she had one chance and that was a bone marrow transplant.

After testing members of her family for a potential bone marrow donor, her sister Annette was found to be a match.

"It was so unbelievable it was like looking through a haystack to find a needle, that's how rare it was," she said.

"My sister was a match, she was always on the plane coming backwards and forwards for tests; she lived in Ireland.

"I was given a 20 per cent chance of survival before I travelled to hospital for treatment.

Alison said that she started to get her finances in check and had planned her own funeral because she did not want to burden her family in case she didn't come home.

Fortunately after the transplant and extensive chemotherapy, Alison survived.

"In 1991 they said 'expect to be in there for about 15 weeks'.

"After 4 weeks I came home," she said.

"The only set back I had was in the February when I got pneumonia and that was the only time I couldn't control my own body, I was given morphine that knocked me out, but I'm still here."

Allison also had a stroke seven years ago, but again survived after having a blood clot removed before it reached her brain.

The 58-year-old former carer from Oadby now owns and runs a shop on Welford Road called Alison's Bits & Bobs.

From that shop she has helped to raise over 2000 for charities such as the Anthony Nolan trust.

She has also now written a book about her life.

"I have had my shop here for two years and have given 2000 already.

"I've walked Ben Nevis, sky dived you name it, I've done it.

"I have a portfolio on my shop window of all the media cuttings from 1991.

"In the first piece that was published I said I would write a book, so I did.

"I started writing it in February in my shop and it took me four weeks, I'm delighted with the book."

The book is filled with her memoirs that detail her struggles throughout her life in great depth.

The money made from sales of the 500 copies she has had printed will be donated to the LRI Haematology ward, Hammersmith Hospital and the Anthony Nolan Trust.

Alison lives with an unrivaled sense of positivity despite her ordeals in life.

"I love it here, I can educate and talk and listen to everyone.

"I think everyone deserves a shot at life, I'm still here, I wouldn't want to be anywhere else.

"I just want to give people hope and strength to get through like I did and that's all I can ask for."

You can purchase of a copy of Alison's book at her shop in Welford Road for 14.99.

View original post here:
The woman who spent 7 years in and out of hospital battling rare condition some doctors had never seen - Leicestershire Live

DuPont, C8 Contamination And The Community Left To Grapple With The Consequences – WVXU

Tommy Joyce is no cinephile. The last movie he saw in a theater was the remake of True Grit nearly a decade ago. "I'd rather watch squirrels run in the woods" than sit through most of what appears on the big screen, he said.

But there's a film that opened Dec. 5 at the Regal Cinemas at Grand Central Mall that's attracting a lot of attention in his community. Dark Waters a legal thriller starring Mark Ruffalo, with a script inspired by a 2016 New York Times article tells the epic story of the DuPont corporation's failure to inform residents of the Mid-Ohio Valley of the considerable health risks of a perfluoroalkyl substance [PFAS] called perfluorooctanoic acid, or C8, for its chain of eight carbons.

The chemical was used in DuPont's production of Teflon and other household products at its Washington Works facility just outside Parkersburg, along the Ohio River. C8 is found in nonstick pans, waterproof clothing, stain-resistant carpets, microwave popcorn bags, fast-food wrappers and hundreds of other products. According to a 2007 study, C8 is in the blood of 99.7% of Americans. It's called a "forever chemical" because it never fully degrades.

DuPont had been aware since at least the 1960s that C8 was toxic in animals and since the 1970s that there were high concentrations of it in the blood of its factory workers. DuPont scientists were aware in the early 1990s of links to cancerous tumors from C8 exposure. But company executives failed to inform the Environmental Protection Agency [EPA] or the public.

Joyce graduated from Parkersburg High School in 1992, went off and earned three degrees and came home. He now serves as mayor of the city of Parkersburg population: 30,000.

Joyce said he's heard more about his community's long struggle with corporate environmental malfeasance in the past few weeks than in his previous two and a half years in office. He attributes this to the release of Dark Waters.

Even David-and-Goliath tales often have complicated backstories, and Joyce knows well that such is the case with Parkersburg and DuPont. "DuPont has been in the Ohio Valley for 70-plus years, and has been a tremendous employer," he said. "Without question, DuPont was the place to work in the Mid-Ohio Valley for a lot of years." Many of his classmates grew up in DuPont families.

Though Chemours, a spinoff company of DuPont, now operates the Washington Works plant, DuPont maintains a presence in the community. A DuPont spokesperson provided an overview of its financial and volunteer support initiatives and wrote that the company supports programs and organizations focused on revitalizing neighborhoods and enhancing quality of life; STEM-related initiatives in local schools; and "initiatives that help protect the environment through clean-up or restoration efforts and allow for DuPont Washington Works to show we are a leader in minimizing our environmental footprint within the community."

Parkersburg, said Doug Higgs, is the kind of town where everybody knows everybody. Higgs graduated from Parkersburg High a year after Joyce, and Joyce's mother, Barbara, taught him Sunday school.

"Everybody knows everybody's business," Higgs said, but nobody talked about C8. It was a matter of "not wanting to bite the hand that fed you."

Well-paying jobs, great benefits, Little League sponsorships, investments in the arts but at a cost. The hand that fed did clench.

Higgs, now an emergency room physician living in Richmond, Virginia, recalls returning from road trips with his family asleep in the back seat, awakened as they approached home by the familiar waft of chemicals.

Two of the Higgs' most immediate neighbors died in their early 50s of renal cell cancer. Higgs' father has ulcerative colitis, and his brother received treatment for polycystic kidney disease in high school.

"We all have stories of friends and family, neighbors, dying too young or being diagnosed with various medical problems," Higgs said.

He knows, of course, the distinction between correlation and causation. But the high incidence of a range of diseases has staggered this community. It's unfair, Higgs said, that a community should have to perpetually ask what exactly it has been exposed to, and where and when the consequences will end.

The Old 'Hey-Look-Over-Here'

DuPont's own documentation specified that C8 was not to be flushed into surface waters, but the company did so for decades. The chemical seeped into the water supplies of the communities of Lubeck and Little Hocking, immediately west of Parkersburg, and the city of Belpre, Ohio, just across the river; and three other water systems.

In 2004, DuPont paid $70 million in a class-action lawsuit and agreed to install filtration plants in the affected water districts. In 2005, it reached a $16.5 million settlement with the EPA for violations of the Toxic Substances Control Act.

A collective decision was made to use the money won in the class-action suit to conduct an epidemiological study in which nearly 70,000 of the 80,000 plaintiffs stopped into one of six clinics set up throughout the community, provided their medical histories and offered their blood. They were each paid $400.

A science panel, comprised of public health scientists appointed by DuPont and lawyers representing the community, was convened to examine the immense database. In 2012, after seven years of study, the panel released a report documenting a probable link between C8 and six conditions: testicular cancer, kidney cancer, thyroid disease, ulcerative colitis, pregnancy-induced hypertension and high cholesterol.

In 2015, DuPont spun off its chemical division into a new company called Chemours, which now occupies the Washington Works facility on the Ohio. In 2017, DuPont and Chemours agreed to pay $671 million to settle some 3,500 pending lawsuits.

"You grew up with the fear of DuPont leaving town," said Ben Hawkins. Hawkins was student body president of the Parkersburg High class of 1993. He remembers DuPont's participation in his school's Partners in Education program and riding in parades on DuPont-sponsored floats.

Among Hawkins' classmates who have been diagnosed with pancreatic cancer was Mike Cox, a local dentist. Cox, Hawkins and Higgs were among a pack of guys who ran together in high school and stayed close after. Cox was a big Ozzy Osbourne fan, and after a grueling regimen of chemo, Hawkins helped arrange backstage passes to a concert, where Osbourne pulled Cox near and shared his own family's experience with cancer. Post-diagnosis, Cox had begun performing stand-up comedy routines that incorporated flute solos. He died Jan. 28, 2017, at the age of 41, a father of three.

Hawkins, who now lives in the Washington, D.C., area, views his Partners in Education experiences somewhat differently today: "It wasn't a partnership; it was a page from a public relations playbook. It was the old 'hey-look-over-here!' move to keep the Teflon dollars flowing into their bank account."

His classmate Beth Radmanesh has similar cynical recollections of DuPont's role in her childhood. Radmanesh grew up less than a mile from the Washington Works plant. Today, she has high cholesterol. Her dad suffers from discoid lupus, causing sores the size of 50-cent pieces on his forehead. Her brother has lupus and had colon cancer, and her sister-in-law has also been diagnosed with lupus.

But Radmanesh said her mom is a proponent of bringing another controversial industry to the valley: fracking for natural gas. "I said to her, 'We've already had our water contaminated once. Do you want your water [to be] flammable? Because that's what will happen.' " Her mom's response was, "'Oh, Beth.' That's it. 'Oh, Beth.' "

A 'Weird Mix'

Joe and Darlene Kiger live just a few miles from where Radmanesh grew up. Joe, a physical education teacher, is now quite well known in the community for having raised awareness of the dangers of C8 called "the devil's piss" by some in local water supplies. He and his wife, Darlene, joined the class-action suit that was settled in 2004.

Darlene said that when she and Joe are out around town, "there are a lot of whispers behind your back. They don't know what to say." The experience has taken a toll "these people all looking at you as bringing this on them," Joe said but they've never considered leaving. "Why would you leave the fight?" he said. "What would it look like if we packed up?"

There's a lot, Joe said, that DuPont hasn't yet been held accountable for. Earlier this year, Chemours was cited by the EPA for the unregulated release of new chemical compounds from its West Virginia and North Carolina facilities. "I'm not done yet," Joe said.

Harry Deitzler served as a lead attorney, among others, in representing the Kigers and tens of thousands of others in the class-action suit. Deitzler was the architect of the decision to use the $70 million to conduct the study.

"Parkersburg adopted me in 1975," Deitzler said of his arrival in town. He'd come for a summer internship in the prosecuting attorney's office. The position didn't pay enough to cover his room and board, so he took a job in a bar called Friar Tuck's.

"By the end of the summer, the community was my family," Deitzler said. "I asked the prosecutor if he'd hire me as an assistant the next year, and he said, 'Sure; you'll get $6,000 a year.' And I said, 'That'll be great.'"

"Most people thought I was a recovering alcoholic because I never drank a beer, because I couldn't afford to buy one." Three years later, at 27, he was appointed as prosecuting attorney. "Such a wonderful, accepting community."

But, some three decades later, there was a price to pay for taking on DuPont.

"There was a misperception that we were trying to put DuPont out of business, and, of course, that was created intentionally by the people in Wilmington," Deitzler said, referring to DuPont's Delaware headquarters. "When you have a community of that size, and you've got several thousand people employed there, and multiply that by the families and their relatives it's very upsetting." Some folks were unsure of what to make of Deitzler.

Longtime resident Nancy Roettger characterizes the community's reaction to the revelation of what DuPont had done as a "weird mix."

"There were women that immediately went out and changed their frying pans," Roettger said. But a lot of those same people decided "that Harry Deitzler is a horrible person" for his role in exposing DuPont.

"It's like, they don't want that frying pan anymore," she said, "but they don't want anything negative, and they're very resentful of the people that stirred up the trouble."

Less Than Idyllic In Retrospect

Candace Jones, a neighbor and longtime friend of Roettger's, said she hates the perception that the community has been divided between the DuPonters and everyone else.

"We're a community and we all need each other," Jones said. "I think it's terrible, absolutely horrendous what happened because of decisions made for monetary gain. But I don't believe we can blame the everyday worker." Her father-in-law worked in the Teflon division. "He just went to work every day; he provided for [his family]."

Jones' friend Janet Ray's husband passed away 16 years ago from pancreatic cancer. He worked for BorgWarner, a manufacturing company on the river. There are about a dozen houses along Ray's street in Vienna, a Parkersburg suburb, "and I think just about every house during the time I've lived on the street has been affected by cancer."

Ray said she sometimes feels guilty, thinking that perhaps the livelihood her family has enjoyed as a result of her husband's employment might have caused health problems for others. "I certainly hope it didn't."

Tracy Danzey was raised in the quiet of Vienna, there with the Rays, the Joneses, the Higgs family. She now lives on the other side of the state, in West Virginia's Eastern Panhandle. Danzey was a competitive swimmer growing up. When not competing, "we were on the river we were playing in the creeks. I was always in the water."

"It's hard to look back at that time now and see it as idyllic," Danzey said.

At age 20, her thyroid began malfunctioning. Five years later, the socket of her hip shattered while running with her husband. She was diagnosed with an atypical form of bone cancer in her right hip. Her hip and leg had to be amputated; she underwent 18 months of high-dose chemotherapy.

Six leading pathologists from across the country were unable to identify the specific type of cancer. "They said it's very pathologically unusual." Research has indicated to Danzey, who's a nurse, that pathologically unusual cancers are not uncommonly associated with industrial poisonings.

Danzey's stepfather is retired from DuPont and her stepbrother works on the Teflon line. "Yes, it is complicated," her mother, Carolyn Tracewell, said. When her kids were growing up, when someone was hired at DuPont, "therewas a celebration" the good pay, the benefits, "and they did treat their employees well."

But "my heart hurts," Tracewell said, to think that her daughter's illnesses might be a consequence of all that.

Danzey said her mom "mostly just feels pain for me," worries about her stepson and is anxious about the future. Her stepfather wonders if one day his pension check will no longer arrive as a result of all the financial fallout.

None of them argue with Tracy about the source of her illnesses. "They know what happened." They allow her "to sit in this truth regardless of how it affects them." That means a lot.

Danzey is among those who believe that in regard to perceptions of DuPont in the Parkersburg community, there's a generational divide: Those in their 40s and younger tend to hold a less charitable view than baby boomers and their parents.

There likewise appears to be a generational divide in willingness to drink the water, despite the filtration installed as a result of the settlement.

On the September Saturday afternoon of the annual Parkersburg Paddlefest, kayaker Travis Hewitt, 31, stood ashore of the point where the Ohio meets the Little Kanawha and said that few people he knows truly believe the water's safe. Sure, he paddles in it, but "I try not to get it on me" and never swims in it. He has a filter installed in his kitchen.

Home

Tommy Joyce, the mayor of Parkersburg, is bullish on West Virginia: "We've got enough coal to light the world, gas to heat the world and brains to run the world."

Fellow Parkersburg High grad Brian Flinn, an engineer, worked for DuPont for eight and a half years; he worked with the raw materials of Teflon. He's seen both sides. He's heard, "If DuPont leaves, we're done. This area will be like most other towns in West Virginia; it'll collapse." He's also aware of the inherent dangers in living within the shadow of the chemical industry. So the sentiment goes, he said, "You take the good with the bad, right?"

But Danzey is unwilling. "I love West Virginia," she said. "I really do. I love this state. I don't want to be anywhere else." But she wants better for West Virginians. Industries come into their communities, do well for a while, "screw up the environment and then leave."

"It's time for something new in West Virginia," she said. "It's time for us to expect more."

Pondering that future keeps Ben Hawkins up at night. "What's next? What's next for the community, and where does this end? Or does it? What sort of positivity can come to that community? They need it and they deserve it."

Hawkins asks this: Think about how loyal the people of the Parkersburg community have been to DuPont. What if they had the opportunity to extend that same loyalty to a company that's equally invested in the economic, physical and emotional health of the community?

"That's home and always will be home," Hawkins said of Parkersburg. "We came from that community and that community did a lot to shape us. We all want the best for that community whatever form that can take."

Taylor Sisk, a Nashville-based healthcare reporter, authored this story for 100 Days in Appalachia. He can be reached at wtsisk1@gmail.com.

Good River: Stories of the Ohio is a series about the environment, economy and culture of the Ohio River watershed, produced by seven nonprofit newsrooms. To see more, please visit ohiowatershed.org

Follow this link:
DuPont, C8 Contamination And The Community Left To Grapple With The Consequences - WVXU

Global Amniotic Membrane Market 2020-2024 | Evolving Opportunities with Celularity Inc. and Human Regenerative Technologies LLC | Technavio – Business…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global amniotic membrane market since 2019 and the market is poised to grow by USD 1.48 billion during 2020-2024, progressing at a CAGR of more than 13% during the forecast period. Request a free sample report

Read the 145-page report with TOC on Amniotic Membrane Market Analysis Report by Geography (Asia, Europe, North America, and ROW), Type (Cryopreserved amniotic membrane and Dehydrated amniotic membrane), and the Segment Forecasts, 2020-2024.

https://www.technavio.com/report/amniotic-membrane-market-industry-analysis

The market is driven by the rising demand for biocompatible scaffolds. In addition, the rise in the development of new applications through research is anticipated to boost the growth of the amniotic membrane market.

The rising need for naturally derived materials in tissue scaffolding is increasing the demand for amniotic membranes. This is due to the specialized structure of amniotic membranes that exhibit high biological viability, making them ideal for creating bio-scaffolds. Moreover, the epithelial cells in amniotic membranes have the advantages of stem cells which provide a native environment of cell seeding. Bio-scaffolds are widely used in regenerative therapies for the treatment of bone, cartilage, skin, vascular tissues, and skeletal muscles. With growing geriatric population, the demand for such orthopaedic regenerative therapies is expected to increase significantly during the forecast period. This will have a positive impact on the demand for amniotic membranes.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Amniotic Membrane Market Companies:

Celularity Inc.

Celularity Inc. operates its business through the Unified Business Segment. BIOVANCE is the key offering of the company. It offers a decellularized, dehydrated human amniotic membrane allograft that contains natural extracellular matrix (ECM) that helps in wound regeneration and tissue restoration.

Human Regenerative Technologies LLC

Human Regenerative Technologies LLC operates the business across segments such as Flowable and Membrane. HydraTek amniotic membrane products, is the key offering of the company. It includes thin and thick dehydrated amniotic membranes used in covering and protecting the recipient's tissue.

Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corp. operates its business across segments such as Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers a wide range of amniotic membrane products. Some of the key offerings include AmnioExcel Amniotic Allograft Membrane, BioDDryFlex Amniotic Tissue Membrane, BioDOptix Amniotic Extracellular Membrane, and Integra BioFix Amniotic Membrane Allograft.

Katena Products Inc.

Katena Products Inc. operates the business across segments such as Instruments, Biologics, Plugs, Lenses, Devices, and Blink Medical. Amniotic Membrane Surgical and Amniotic Membrane Clinic are some of the key offerings of the company.

MiMedx Group Inc.

MiMedx Group Inc. operates the business in the Regenerative biomaterial products and bioimplants segment. The company offers a wide range of amniotic membrane products. AmnioFix, EpiFix, and EpiBurn are the key offerings of the company.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Amniotic Membrane Type Outlook (Revenue, USD Billion, 2020 - 2024)

Amniotic Membrane Regional Outlook (Revenue, USD Billion, 2020 - 2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Healthcare include:

Global Extracorporeal Membrane Oxygenation Machines Market Global extracorporeal membrane oxygenation machines market by geography (Asia, Europe, North America, and ROW) and modality (veno-venous and arterio-venous; and veno-arterial).

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Global Duchenne muscular dystrophy (DMD) therapeutics market by type (biologics and small molecules) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com

Read more:
Global Amniotic Membrane Market 2020-2024 | Evolving Opportunities with Celularity Inc. and Human Regenerative Technologies LLC | Technavio - Business...

Sight loss research needs urgent investment – The Guardian

As leading ophthalmologists and researchers we are joining the eye research charity Fight for Sight to call for urgent action on blindness in 2020 to address the research funding gap.

We know that serious sight loss doesnt discriminate it can affect anyone at any time and it is on the increase. Science can already do so much and with the advent of new gene therapies and stem cell treatments we are so close to outcomes that were not possible a decade ago. Yet so much more needs to be done to develop new universal treatments.

The main barrier is the lack of research funding. It is unacceptable that in 2020 only 1% of UK grant funding goes to eye research, even though more than 20% of people will be affected by serious sight loss in their lifetime. Blindness can have a huge impact on peoples mental health and ability to work, increasing costs on health systems and infrastructure.

In 2019 the WHO and UN general assembly both outlined that globally more investment is needed into sight loss and research. We are calling for the new government and its partners to agree a national plan on sight loss and a research agenda that will help to ensure that eye research gets the funding it badly needs. Please join us at fightforsight.org.uk and let 2020 be the year that we accelerate progress in beating blindness.

Prof Chris Hammond Frost chair of ophthalmology, Kings College London, Prof Alan Stitt Dean of innovation and impact, Queens University Belfast, Prof Alastair Denniston Consultant ophthalmologist, Birmingham University, Prof Alison Hardcastle Professor of molecular genetics, UCL Institute of Ophthalmology, Prof Lynda Erskine Chair in developmental neurobiology, Aberdeen University, Prof Jeremy Guggenheim Director of research, Cardiff University, Prof David Steel Honorary clinical senior lecturer, Newcastle University, Prof Chris Inglehearn Professor of molecular ophthalmology and neuroscience, Leeds University, Prof Timothy Jackson Consultant ophthalmic surgeon, Kings College London, Prof Rachael Pearson Professor of developmental neuroscience, UCL Institute of Ophthalmology, Prof Jessica Teeling Professor of Experimental Neuroimmunology, University of Southampton, Prof Colin Willoughby Professor of ophthalmology, Ulster University

Join the debate email guardian.letters@theguardian.com

Read more Guardian letters click here to visit gu.com/letters

Do you have a photo youd like to share with Guardian readers? Click here to upload it and well publish the best submissions in the letters spread of our print edition

Go here to see the original:
Sight loss research needs urgent investment - The Guardian

Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner – Seeking Alpha

Investment Thesis

Forty Seven (FTSV) management must be pleased with the progress they made in December '19.

First of all, early results from clinical trials of the company's flagship drug magrolimab were positive. In a trial evaluating magrolimab in combination with azacitidine for the treatment of myelodysplastic syndrome ("MDS") and acute myeloid leukaemia ("AML"), Complete Response ("CR") rates of 50% and Overall Response Rates ("ORR") of 92% were observed in untreated patients with higher risk MDS.

In Patients with Untreated AML who are ineligible for induction chemotherapy CR and ORR rates were 55% and 64% respectively. Furthermore, the combination of magrolimab and azacitidine was well tolerated, meaning the treatment may be safe for fragile, sicker and older patients.

The strong results appeared to take the market by surprise and Forty Seven's share price accelerated immediately. The stock gained 84% on 28x average volume in a single day to reach $39 and continued its ascent to reach an all-time high of over $44 (price at the time of writing is a little lower at just over $38).

Secondly, after releasing the results Forty Seven management wisely decided to issue a public offering of 5.59m shares at $35 per share, successfully raising $195.6m. (Source: Bloomberg). Given that the last fundraising, in July of last year, raised $86m at an offer price of just $8, the latest raise must be a cause of satisfaction. It is also a clear indication that investors are starting to see Forty Seven and magrolimab as the frontrunner amongst a plethora of biotechs focused on CD-47 directed therapies, in my view.

The company reported cash, cash equivalent and short-term investments of $166.7m on its Q319 earnings call which includes proceeds from the July raise and a $15.7m upfront licence payment from a collaboration with Ono Pharmaceuticals (Source: Globenewswire) which will see the Japanese firm develop, market and commercialise magrolimab across Japan and the ASEAN region.

Management stated this funding would be sufficient for Forty Seven to support its operations - which include up to ten clinical trials of magrolimab plus pre-clinical trials of anti-SIRPa antibody FSI 189 and anti-cKIT antibody FSI-174 - through to the first quarter of 2021.

Factor in December's raise and we can see that Forty Seven is now in a strong position to pursue and meet its stated goal of being the first company to release an approved therapy targeting the CD47 checkpoint of the innate immune system.

This being biotech, there are many reasons why Forty Seven's best efforts may fall short of winning approval for commercialisation from the FDA. Magrolimab is still in the early stages of being tested and its good results to date will count for nothing should Phase II or III trials reveal safety concerns or a failure to meet the primary endpoint.

Forty Seven does not have a strong pipeline to fall back on should magrolimab ultimately fail to secure commercialisation, meaning investing at this time comes with a high chance of making a loss.

A rival company could produce a CD47-directed treatment that proves to be more effective in which case Fifty Seven will struggle to sell magrolimab even if it is approved. Clinical tests could go on for longer than expected requiring further funding and there is no guarantee the company will be able to raise enough cash. Or, an alternative therapy, such as gene editing or RNAi could outperform all other treatments, rendering the company's development efforts fruitless.

Despite these concerns, however, if I were to pick a CD47 focused immunology company to back today, it would be Forty Seven. With no current concerns on the funding front and with such impressive early trial results from its lead candidate the near-term future certainly looks bright.

There are further reasons for optimism. The company owns exclusive rights to magrolimab which means should the drug be approved Forty Seven will retain the bulk of the profits from its sale. If results continue to impress Forty Seven represents an attractive acquisition target for a big pharma firm. And perhaps most importantly, besides MDS and AML magrolimab has the potential to be approved for numerous indications. Non Hodgkin's Lymphoma, for example, as well as ovarian cancer, colorectal cancer and bladder cancer.

In other words, magrolimab has blockbuster potential, and therefore, despite the obvious risks - one bad trial result could decimate the current share price - in my view Forty Seven should be carefully considered as an investment due to its upside potential. There has not been a new treatment available for Myelodysplastic syndromes ("MDS") in over a decade. Some investors may feel the rewards on offer for a successful treatment are significant enough to justify the risks.

Forty Seven was founded in 2014 in Menlo Park, California by a group of Stanford scientists, most notably Irv Weissman. Weissman played an instrumental role in identifying and developing CD47 as a potential cancer treatment.

Forty Seven went public in June 2018. The company raised $112m at a price of $16 giving it a valuation just shy of $480m. Today, thanks to the recent share price gain, Forty Seven's market cap stands at over $1.5bn.

Forty Seven's lead drug candidate magrolimab is an anti-CD47 antibody formerly known as 5f9. 5f9 has the ability to "switch off" the "don't eat me" signalling pathway used by cancerous cells to avoid detection by macrophages.

Macrophages are the innate immune system's first line of defence against abnormal cells. CD47 is expressed by healthy cells as a means of sending a "don't eat me" signal to macrophages, thereby exempting themselves from a process known as phagocytosis whereby a macrophage consumes abnormal cells to protect the body.

Nearly all cancerous cells over-express CD47 as a means of disguising themselves against macrophages to avoid being swallowed up and eliminated. The "don't eat me" message is sent when the cancerous cell binds to a receptor on macrophages known as SIRP-alpha.

Weissman's research at Stanford demonstrated three things. That blocking the "don't eat me" signalling pathway leads to elimination of many types of tumours and increases a patient's chances of survival. That boosting "eat me" signals found on cancer cells using therapeutic antibodies can work in conjunction with blocking CD47. And that, besides phagocytosis, macrophages activate tumor specific antigens that can activate T-cells against the cancerous cells, meaning that blocking CD47 can also work in conjunction with T-cell based therapies. (Source: FTSV Fundraising prospectus Dec '19)

FTSV 3-fold strategy. Source: FTSV Website

This has led directly to Forty Seven's three pronged development strategy. Monotherapy, e.g. facilitating phagocytosis, synergizing with other tumor targeting antibodies and T-cell activation, and using pro-phagocytic signals on tumor cells in conjunction with chemotherapy.

5F9 is a humanized IgG4 subclass monoclonal antibody that Forty Seven say is designed to combine with a proprietary dosing regimen to help overcome the toxicity limitations of rival anti-CD47 therapies developed by other companies.

Besides 5F9 / magrolimab, Forty Seven are also advancing FSI-189, an anti-SIRPa antibody, and FSI-174, an anti-cKIT antibody. FSI-189 is expected to enter solid-tumor trials this year, whilst cKIT - an antibody targeting stem cell growth factor inhibitors and issuing an "eat me signal" - may prove effective in treating leukemia, melanoma and gastrointestinal stroma tumors.

Forty Seven has 6 clinical trials of magrolimab ongoing that have progressed beyond the pre-clinical stage.

The trial that has produced the most positive results to date (referred to in the introduction of this article) is evaluating magrolimab both as a monotherapy and in conjunction with azacitidine as a treatment for MDS and AML in patients with haemotological malignancies.

Trial investigator David Sallman, M.D., H Lee Moffit Cancer Center and Research Institute had this to say on the publication of the encouraging early data:

The data that continue to emerge from this clinical trial are incredibly exciting, suggesting that the combination of magrolimab and azacitidine may offer the first new therapeutic regimen in over a decade, with the potential to induce meaningful and lasting responses in patients with higher-risk disease. Importantly, these results also support magrolimabs tolerability profile, further differentiating it as a safe treatment that may be used even in more fragile, sicker, and older patients.

Forty Seven have subsequently entered discussions with the FDA with regard to initiating a registration-enabling program with the goal of securing accelerated approval, and also hope to submit a biologics license application ("BLA") in Q421.

MDS is regarded by Forty Seven management as one of its most important treatment targets given its high incidence in the US (as illustrated in the chart below) and due to the paucity of treatment options available to patients.

Source: FTSV Investor Presentation Dec '19

Research suggests that 75% of MDS patients receive only supportive care with the only other options: chemotherapy drugs Vidaza (the brand name version of azacitidine), revlimid and Dacogen, or allogeneic stem cell therapy, being ineffective.

As we can also see from the above chart, diffuse large B-cell lymphoma ("DLBCL") represents another target for Forty Seven and it is the subject of a second planned clinical trial of magrolimab, this time in conjunction with rituximab, a monoclonal antibody that targets a protein known as CD20.

The trial will enrol 100 patients who have failed at least two prior lines of therapy, and will begin, management say, in Q120 with the earliest interim efficacy data slated to be made available in Q420. On the Q319 earnings call Forty Seven CEO Mark McCamish stated his desire to advance into earlier lines of treatment as early as possible referring to a "substantial unmet need" in treatment of DLBCL.

McCamish also updated investors and analysts concerning the phase 1b solid tumor trials. Results from both magrolimab combined with avelumab to treat patients with brain cancer, and in combination with cetuximab in patients with colo-rectal cancer will be made available in meetings scheduled for Q120 with abstracts of early data having already been submitted.

McCamish also announced a collaboration with gene therapy specialists Bluebird Bio. Forty Seven intend to leverage Bluebird's LentiGlobin platform to evaluate FSI-174 and move forward the cKIT program with a focus on pretransplantation and avoiding the need for chemotherapy or radiation toxicities or secondary malignancies when performing stem cell transplants.

Targeting blood-forming stem cells that express cKIT with FSI-174 releases macrophages to clear the steam cells, and, used in conjunction with magrolimab could, McCamish says:

massively expand the number of patients eligible for transplantation and therefore enable many more people to benefit from the curative potential transplantation.

During Q3 Forty Seven had an R&D spend of $27.1m - up from $18m in Q318, ascribed to the advancement of clinical trials and contract manufacturing costs for the proposed BLA.

In total, the company made a loss of $15.1m, down from $21.7m the previous year. In the first nine months of 2019 losses totalled $61.2m. As mentioned previously, Forty Seven should have more than enough funding to complete its trials and submit the BLA without having to dilute investors further - but it would be wise not to rule anything out. One failed trial could set the whole process back by years. (Source: FTSV 10Q Submission Q319).

There is no doubt that Forty Seven faces stiff competition. Amongst the companies competing in the CD47 antibody space are Surf therapeutics (SURF), Trillium Therapeutics (TRIL), Celgene (CELG), China based biotech Innovent Biologics, and Netherlands Based Aurigene and Synthon. (Source: PM Live)

All are worth studying in more detail and both SURF and TRIL represent a far cheaper investment opportunity, with shares priced at just $1.94 and $1.26 respectively. Neither have experienced a "Forty Seven moment", delivering outstanding results from early stage trials, but the price of Trillium recently spiked as Morgan Stanley reported a 5% holding. (Source: Benzinga)

For my money, however, Forty Seven is the frontrunner, and although it is priced at a premium to some of its rivals, there are good reasons for this, as I have discussed above. Another reason Forty Seven is at a competitive advantage is the 187+ patents it owns protecting magrolimab and FSI-189.

Additionally, although it was painful at the time, in 2018 Forty Seven agreed to make $47m of milestone payments to Synthon to secure non-exclusive rights to several CD-47- and SIRPa- directed antibodies, including rituximab. Other companies will need to make similar agreements if they want to develop their drugs with the same freedom that Forty Seven now has. Further analysis can be found in this informative recent SA article.

The average analyst price target for Forty Seven at time of writing is $39.25 (Source: Nasdaq) with a high of $48 and a low of $35 with the majority of analysts issuing "buy" ratings for the stock.

In my view, provided trial results remain positive, each new development can move the share price higher. Given the size of the addressable market (the global market for MDS treatment alone is set to reach $2.4bn by 2022, at a CAGR of 9.7% according to research from Grand View) and the urgent need for new and better treatments for diseases such as NHL, MDS, AML and DLBCL, the potential upside here is substantial.

If Forty Seven were to perform as well as, for example, gene-silencing treatment developer Arrowhead (ARWR) has done in 2019, buoyed by positive data, the share price could easily double as Arrowhead's has done. That is a big "if", however.

Biotech investing is inherently risky and it is all too easy to get sucked into a "next big thing" such as CD47 antibodies. In Forty Seven's case, however, the exciting premise is backed by years of research and real clinical data. Importantly, the FDA has issued Forty Seven with accelerated approval status both for magrolimab as a treatment for MDS, AML and DLBCL, as well as follicular lymphoma.

The company has treated over 190 relapsed or refractory cancer patients with magrolimab and will shortly enter a pivotal phase III trial, ENHANCE, enrolling 90 new patients to evaluate the combination of azacitidine and magrolimab together, plus it has the BLA scheduled for submission before the end of 2021.

The management team are experienced with big pharma backgrounds including Abbott Laboratories, Amgen, Genentech, Gilead, Janssen Global Services, LLC, PDL Biopharma, Inc. and Sandoz Inc.

Furthermore, Forty Seven has agreed collaborations with big pharma companies Merck and Genentech, a subsidiary of the Roche group to explore opportunities within ovarian and bladder cancer.

On balance, I think there are enough positive signals to make Forty Seven are worthwhile, if speculative investment.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Visit link:
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner - Seeking Alpha

What the standard health insurance product offers – Livemint

With a host of health insurance policies available in the market, buyers often get confused and do not know how to compare them. To curb this confusion and to encourage more people to buy health insurance, the Insurance Regulatory and Development Authority of India (Irdai) has mandated all general and health insurers to offer a standard individual health insurance product with a maximum sum insured of up to 5 lakh. Find the circular, which was issued last week.

The product will be named Arogya Sanjeevani followed by the insurers name. It will have to be made available starting 1 April 2020. Standardization of a product offering will help customers get a parity-based understanding of product benefits, simplifying the purchase decision. It leaves no room for ambiguity for the customer in terms of product comparison, since they are assured of the fact that other insurers do not offer a different coverage," said Anuj Gulati, managing director and chief executive officer, Religare Health Insurance Co. Ltd.

While a standard product will surely simplify health insurance for you, do keep in mind that this may not be the best product in the market. We give you the features and details of the new standard plan.

Main features

Like a typical health insurance plan, Arogya Sanjeevani will be an annual policy renewable for life and will pay for hospitalization expenses. This means costs incurred on the surgeon, anaesthetist, consultants, specialist fees, operation theatre charges, oxygen, surgical equipment, costs towards diagnostics and so on are covered too. Further, expenses incurred on hospitalization under the Ayush system of medicine will also be covered without any sub-limits. Pre-hospitalization (from 30 days prior to the date of admission) and post-hospitalization expenses (60 days from the date of discharge) will be included too.

The policy will also cover dental treatment and plastic surgery necessitated due to a disease or injury, all day-care treatments and expenses incurred on road ambulance. The ambulance expenses will be capped at 2,000 a day.

Anyone between 18 and 65 years can buy this product, but it cant be customized to your needs.

However, there are some important caveats to consider. The policy will cover room, boarding and nursing expenses but only up to 2% of the sum insured, subject to a maximum of 5,000 a day.

Gurdeep Singh Batra, head, retail underwriting, Bajaj Allianz General Insurance Co. Ltd, said the intention of the policy is to insure the non-insured population of the country, particularly in tier-2 and tier-3 cities, which is why the sum insured is capped at 5 lakh. Room rent makes for a large chunk of the hospitalization expense and not having a cap would push the premiums. Instead of a 1% cap, theyve capped it at 2% or 5,000, which is reasonable because in tier-2 and tier-3 cities, most nursing homes and hospitals offer good rooms within 5,000," said Batra.

The policy also covers expenses on intensive care unit (ICU) and intensive cardiac care unit (ICCU) facilities up to 5% of the sum insured, up to 10,000 a day.

The mandatory covers prescribed by Irdai are inclusive enough for a standard product but this could have been enhanced by increasing some of the limits restricting the coverage such as cap on room rent, pre- and post-hospitalization expenses, and restricting ambulance charges up to 2,000 per hospitalization. Existing products offered by insurers offer flexibility and superior covers with no capping on room rent or a cover for more number of pre- and post-hospitalization days along with higher limits for ambulance," said Biresh Giri, appointed actuary, head of product development and chief risk officer, Acko General Insurance Ltd.

The product will come with a fixed co-pay of 5%, across all age groups. A 5% co-payment clause would mean that you will pay 5% of the claim amount and the insurer will pay the rest.

Theres also a limit on how much the policyholder can claim for cataract surgery. Irdai said, for each eye, expenses incurred on the treatment of cataract will be covered only up to 25% of the sum insured or 40,000, whichever is lower. Irdai has also listed the conditions that insurers shall cover after a prescribed waiting period.

What is positive about this policy is that it takes into account the ever-evolving healthcare ecosystem. The policy will cover modern treatments like stem cell therapy and balloon sinuplasty up to 50% of the sum insured. This (including modern treatments) is a good proposition from an insured viewpoint. Currently, other products are also being re-looked for such extended coverage in line with guidelines issued on standardization of exclusions in health insurance," said Batra.

Premiums and bonus

The regulator has allowed insurers to determine the price of the policy keeping in view the mandatory covers they would need to offer. Insurers, however, will have to comply with Irdai norms while doing so. Pricing for any insurer is a factor of risk assessment, estimated claims, consumer behaviour and long-term sustainability of the product.

The range of pricing should largely be similar for most insurers but its too soon to be sure, said Gulati.

While insurers are not allowed to offer any add-ons or optional covers with this product, they can package it in the form of a family floater plan where the premium is decided based on the age of the oldest member of the family. Giri said the premiums could start from 5,000 for an individual policy with a sum insured of 5 lakh and 15,000 for a family floater plan with a sum insured of 5 lakh.

Note that a cover of 5 lakh may not be sufficient for a whole family but is still better than having no insurance at all. For a floater policy, 5 lakh may not be adequate. Nevertheless, we have a huge untapped market where most people dont have any insurance and are paying out of their own pockets or not getting properly treated," said Prasun Sikdar, MD and CEO, ManipalCigna Health Insurance Co Ltd. Like other health products, policyholders will get the option of paying premiums on a monthly, quarterly, half-yearly and annual basis. The cumulative bonus on this product, according to Irdai, shall increase by 5% in respect of each claim-free year, subject to a maximum of 50% of the sum insured but only if the policy is renewed without a break. If a claim is made in any particular year, the bonus will decrease at the same rate at which it was accrued: 5%. Also, no deductibles are allowed.

Mint take

Sikar said it is difficult to say whether premiums will drive this product or awareness campaigns by Irdai, or the brand name of the insurers. But this will definitely benefit the industry and increase penetration," he added. Batra said this product is specifically targeted towards the lower middle-income group where medical expenses, especially the cost of hospitalization is still lower than metro cities.

Experts also said that this may impact the retail health insurance business in the long run as it will bring more uniformity and standardized policy wordings, making it easier for customers to choose.

However, keep in mind that this policy suffers from two major setbacks: room rent capping and co-payment. While this may make the policy affordable, in case of a claim, you will have to shell out a part of the claim from your pocket. Given the low sum insured, this policy comes with restrictive clauses that also make it more affordable. Before you buy the new standard product, compare the premiums and choose the least restrictive option. If you havent bought a policy due to high premiums, this can be a good entry point. Whether the product will enhance the adoption of health insurance remains to be seen.

View post:
What the standard health insurance product offers - Livemint

Global Animal Stem Cell Therapy Market- Industry Emerging Trends, Future Growth and Productivity Data Analysis, Reliability, Competitive Analysis and…

Global Animal Stem Cell Therapy Market Research Report 2019 to 2023 segmented by product type, applications and offers complete details including recent trends, Animal Stem Cell Therapy statistics, and growth factors to assist the users in planning the business strategies and prioritize the business which will lead to huge market returns.

Animal Stem Cell Therapy market has dominated many regions of the world in past few years. According to the global Animal Stem Cell Therapy market report, it will continue to rule in upcoming years. The ever-increasing demand for the Animal Stem Cell Therapy market and various business opportunities have boosted the growth.

Request for sample copy of market report @: https://www.globalmarketers.biz/report/life-sciences/2018-global-animal-stem-cell-therapy-industry-research-report/118224 #request_sample

Global Animal Stem Cell Therapy Market Report Scope:

Research Report offers a forecast for the global Animal Stem Cell Therapy market between 2019 and 2023. In terms of value, the Animal Stem Cell Therapy industry is expected to register a steady CAGR during the forecast period. This study demonstrates the Animal Stem Cell Therapy market share dynamics and trends globally across the various regions. This influence the current nature and the future status of the Animal Stem Cell Therapy industry during the forecast period.

This research report provides a thorough global Animal Stem Cell Therapy market study and provides insights about the several factors driving the popularity of Animal Stem Cell Therapy and its features. The report includes an extensive analysis of the key drivers, restraints, structure and Animal Stem Cell Therapy market trends, stakeholder strategies and necessities for succeeding in the business.

Global Animal Stem Cell Therapy Report Segmentation: The report segregates the Animal Stem Cell Therapy market based on the key vendors, industry vertical, product category, and across different regions globally. The Animal Stem Cell Therapy industry is expected to witness moderate revenue growth during the forecast period.

Different product categories include:

DogsHorsesOthers

Global Animal Stem Cell Therapy industry has a number of end-user applications including:

Veterinary HospitalsResearch Organizations

A thorough analysis has been provided for every segment of the business in terms of Animal Stem Cell Therapy market size across diverse regions. This section provides a detailed analysis of the key Animal Stem Cell Therapy market trends in each region.

Global Animal Stem Cell Therapy Market Regional Analysis:

The next section of the report consists of a detailed analysis of the Animal Stem Cell Therapy market across various countries in different regions. It provides a Animal Stem Cell Therapy industry outlook for 20192023 and sets the forecast within the context of the Animal Stem Cell Therapy market research to include the latest technological developments as well as offerings.

South America Market (Brazil, Argentina)

The Middle East & Africa Market (South Africa, Saudi Arabia)

Europe Market (Spain, U.K., Italy, Germany, Russia, France)

North America Market (U.S., Mexico, Canada)

Asia-Pacific Market (China, Japan, India, Southeast Asia)

Inquire Here For Queries Or Report Customization:: https://www.globalmarketers.biz/report/life-sciences/2018-global-animal-stem-cell-therapy-industry-research-report/118224 #inquiry_before_buying

This study discusses the key trends within countries that contribute to the Animal Stem Cell Therapy market development as well as examines the degrees at which the drivers are influencing the marketplace in each region. The global Animal Stem Cell Therapy industry report assesses the present situation and the development prospects of the Animal Stem Cell Therapy market in various regions worldwide.

Global Animal Stem Cell Therapy Market Report Highlights:,

In the final section of the Animal Stem Cell Therapy market report, we have comprised a competitive landscape to provide clienteles a dashboard view based on the categories of providers in the value chain, their occurrence in the Animal Stem Cell Therapy portfolio and key differentiators in the global Animal Stem Cell Therapy market. This section is primarily intended to provide clients with an objective and detailed comparative valuation of the key providers specific to a market segment in the Animal Stem Cell Therapy supply chain and the major players in the market.

Table of Content:

Chapter One: Animal Stem Cell Therapy Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Animal Stem Cell Therapy Market Competition, by Players

Chapter Four: Global Animal Stem Cell Therapy Market Size by Regions

Chapter Five: North America Animal Stem Cell Therapy Revenue by Countries

Chapter Six: Europe Animal Stem Cell Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Animal Stem Cell Therapy Revenue by Countries

Chapter Eight: South America Animal Stem Cell Therapy Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Animal Stem Cell Therapy by Countries

Chapter Ten: Global Animal Stem Cell Therapy Market Segment by Type, Application

Customization of the Report: Customization can be provided on the basis of clients requirements. Get in touch with our sales team ([emailprotected]s.biz)

Browse full report @ https://www.globalmarketers.biz/report/life-sciences/2018-global-animal-stem-cell-therapy-industry-research-report/118224 #table_of_contents

Read more here:
Global Animal Stem Cell Therapy Market- Industry Emerging Trends, Future Growth and Productivity Data Analysis, Reliability, Competitive Analysis and...

Super Naturals: the high-tech natural beauty brands changing the face of modern skincare – Evening Standard

The latest lifestyle, fashion and travel trends

A high-end bio-beauty boom is in full bloom thanks to a host of revolutionary brands set on changing the face of modern skincare. These are the five to know...

Hailing from the Napa Valley, where founder April Gargiulo spent two years researching and developing her Holy Grail skincare products using the same meticulous approach her family took to their fine wine business, Vintners Daughter champions just two products that promise dramatic, multi-correctional results using some of the worlds most active organic and foraged botanicals. The original Active Botanical Serum (175) is hailed as the face oils to end all face oils and is built around the brands signature Phyto Radiance Infusion. This process starts with consciously grown whole plants such as calendula and super green alfalfa, known in ancient times as the foods of life, which undergo a methodical three-week long extraction to glean every last drop of their nutritional benefits. Just five drops using the brands 30-second Push/Press Method of application promises to deliver visible radiance, brightness and unparalleled nourishment particularly when used in conjunction with its preparatory Active Treatment Essence (210) (goop.com).

The undisputed Queen of Green, Tata Harper is a pioneer of the farm-to-face beauty movement with all-natural formulations handcrafted in the brands laboratory in Vermont and bottles stamped with a code to trace how fresh your product is and who it was made by. The beauty editors favourite is going one step further with the launch of its Supernaturals 2.0 line of six products boasting 155 ultramodern green ingredients from 46 countries and of course, no synthetic chemicals. The Elixir Vitae Serum (391) alone boasts 34 new radical engineered ingredients from 25 countries, including kelp polymers from France developed to target cellular ageing. Other highlights from the range include the Concentrated Brightening Serum (257), which contains 24 ingredients to hydrate, 17 to reduce wrinkles, 15 to brighten and 13 to even skin tone, and the Boosted Contouring Serum (257), designed to lift, firm and restore youthful elasticity with a combination of Edelweiss stem cells and skin revitalising pomegranate. (tataharperskincare.com)

The brainchild of cosmetologist Anna Buonocore and naturalist Jeanette Thottrup, Seed To Skin believes that effective skincare is threefold. Firstly, that wild ingredients foraged from the land and sea used in conjunction with those sourced from its organic Tuscan farm are among the most potent nature has to offer. Secondly, that just like feeding your body skin requires a healthy, balanced diet and formulas that neither starve nor overload with any one element. Finally, that the most effective absorption relies on a precise mix of perfectly-sized molecules to ensure each ingredient is delivered exactly where it needs to go. As a result, its award-winning product line is loaded with game changers try The AlcheMist Super Active Serum Spray (145) to feed your skin a nutrient-rich drink whenever it needs a boost, or the Black Magic Detoxifying Oxygen Therapy Mask (119) which contains activated charcoal and volcanic clay for a one-stop facial in a jar (libertylondon.com).

(Wildsmith )

Inspired by the arboretums progressive approach to cultivation at Hampshires Heckfield Place and named after its mastermind William Walker Wildsmith, this ethical crafted-in-England skincare brand is designed for those who desire natural products but demand clinical results. Exclusive to Harrods beauty halls, the hero additions to its product line-up include the Platinum Booster (175) a powerful skin-firming treatment powered by encapsulated oxygen and moss cell cultures and a reviving, collagen-boosting Copper Peptide Cream and Serum Duo (150) which delivers a luminous finish to your complexion and comes in a compostable mycelium box (wildsmithskin.com; harrods.com).

After turning to flower arranging as a weekly dose of mindfulness, beauty entrepreneur Kelly S Chung endeavoured to harness the healing power of nature or Flower Therapy, as she has coined it in another form; and Femmue was born. Fusing K-beauty innovation with a clean beauty ethos and the cellular energy of plants, the camellia flower is at the heart of the range and renowned for its antioxidant and restorative qualities. The Divine Camlia Facial Oil (100) is the purest form with 99.8 per cent camellia seed oil, while other must-try products in the line include the bestselling Flower Infused Fine Mask (40) formulated with camellia petals, geranium oil and cactus extract and the lavender-loaded Brilliant Cleansing Oil (73) (net-a-porter.com).

More:
Super Naturals: the high-tech natural beauty brands changing the face of modern skincare - Evening Standard

Insights on precision oncology developments in Japan and beyond – MobiHealthNews

Cancer has been the leading cause of death in Japan since 1981 and this is compounded by the fact that the country has a hyper-aging society, which means that Japan will face a substantial increase in the number of elderly cancer patients, according to a review article by Matsuda and Saika published in the Annals of Cancer Epidemiology in 2018. Prof Yasushi Goto of the National Cancer Center Hospital in Japan shared with MobiHealthNews on some of the latest developments in precision oncology in Japan, the interest of pharmaceutical companies in targeted therapy and a nationwide cancer genome screening project named SCRUM.

Q. Could you tell us more about your role at the National Cancer Center Hospital?

A. National Cancer Center Hospital (NCCH) is based in Tokyo, Japan and is the largest cancer center in the country. The other is national cancer center is located in Chiba, Japan. One of the special characteristics of NCCH apart from the research institute hospital, is that we also do research for every kind of cancer activity in our hospital. We dont only do clinics, but also genetic oncology, rare cancers.

My main work is at thoracic oncology which mainly covers lung cancer. I also am a member of Rare Cancer Center so I also cover, malignant mesothelioma, thymic cancer, neuroendocrine tumors, and all others. Since Japan has launched national genomic project, and National Cancer Center is playing the central role in this project, I am also joining Section of Knowledge Integration in Center for Cancer Genomics and Advanced Therapeutics.

Q. What are your observations on the development of precision oncology in the APAC region? How would you describe precision oncology in the most straightforward manner?

A. Testing for patients with cancer is prevalent in the APAC region. Compared to other countries, people in Asia are generally accustomed to genetic testing for precision medicine. Our capabilities may not be as advanced as the United States for full gene sequencing, perhaps because of cost issues, but we are catching up.

For precision oncology to develop further, more patients should be tested for genetic testing and target therapy. We are looking to putting in place a proper system to support this right now, especially in the rare cancer field.

There was a recent nationwide project in Japan called SCRUM, conducted by the National Cancer Center East Hospital. SCRUM is the first industry-academia collaboration nationwide cancer genome screening project. I believe early access to drugs is partly due to this project.

Q. Medtech or healthtech startups are also getting into the precision medicine space and seeing a lot of interest from investors. For instance, genomic medicine startup Lucence from Singapore recently raised $20 million in Series A funding. What opportunities do you see in these startups in terms of working together with hospitals such as the National Cancer Centre Hospital? Are there any notable startups in Japan in the precision medicine space?

A. In Japan, many pharmaceutical companies are looking at targeted therapy. Prominent companies include Daichi-Sankyo, Chugai, and Takeda. NCCH is currently working closely with Daichi-Sankyo, Takeda and Chugai.

The approval system is different between blockbuster drugs and targeted therapy. If you only have one patient in Japan and globally there are only 20 or so there can be a scenario where the drug is effective, but it is not approved in our country as there is only a single patient. This is why some pharmaceutical companies are looking at precision medicine.

Companies including Sysmex are also actively looking into the testing of panel sequencing. NCCH has also worked with Sysmex to make a cancer sequencing panel.

Q. The high incidence of cancer in modern societies is worrying and also very costly how do you think precision oncology can help tackle some of these challenges?

A. Cost is a global issue, for both the development side (e.g. the pharmaceutical companies) and the consumption side (e.g. governments, individuals). We also need some basic infrastructure for precision oncology, to screen patients. Currently each drug needs its own testing. With many drugs that need to be tested, we need a platform to do panel sequencing in order to annotate any genetic changes in the patients for treatment.

In Japan, we are now trying to make this infrastructure because the government recently approved the panel sequencing in 2019. This means that after standard therapy, every patient is able to test for panel sequencing. As more patients are screened, in this way I think cancer treatment will be improved in the future.

Q. What do you think will be the key developments and breakthroughs in precision oncology in the next 3-5 years?

A. There will be no blockbuster development, but there will be steady progress in the detecting genetic changes earlier in the next 3-5 years. Some of the topics at the ESMO Asia Congress 2019 in Singapore were on advancements in detecting mutations/previously overlooked genes. Since we are able to find these abnormalities earlier, we now have new anti-cancer agents to target them.

See more here:
Insights on precision oncology developments in Japan and beyond - MobiHealthNews

Pune to host fifth edition of global Drosophila conference – The Hindu

The city is set to host the fifth edition of the Asia Pacific Drosophila Research Conference (APDRC5), which is being organised in the country for the first time by the Indian Institute of Science Education and Research (IISER).

This biennial conference, which is to be held between January 6 and 10, aims to promote the interaction of Drosophila researchers in the Asia-Pacific region with their peers in the rest of the world. It will bring together scientists from all over the world who use the fruit fly, Drosophila, as a model organism to address basic and applied questions.

Drosophila is one of the most widely-used and preferred model organisms in biological research across the world for the last 100 years. Several discoveries in biology have been made using this. Its genome is entirely sequenced and there is enormous information available about its biochemistry, physiology and behaviour, said professor (biology) Sutirth Dey of IISER.

The event will feature 430 delegates: 330 Indian and 100 foreign. It will see the participation of two Nobel laureates, professors Eric Wieschaus and Michael Rosbash, known for their seminal contribution to the fields of development biology and chronobiology respectively.

Prof. Wieschaus, an American evolutionary developmental biologist, shared the Nobel in Physiology in 1995 with Edward B. Lewis and Christiane Nsslein-Volhard for his work on genetic control of embryonic development, while Prof. Rosbash shared the Nobel in 2017 in Physiology along with Michael Young and Jeffrey Hall for their discoveries of molecular mechanisms controlling the circadian rhythm.

This event is one of the largest meetings of Drosophila researchers in the whole world and attracts scientists working in diverse disciplines ranging from cell and molecular biology to ecology and evolution, said Prof. Dey.

Explaining the choice by the APDRC board of IISER to organise the meet, he said the institute is one the premier scientific research institutes of the country and is very strong in Drosophila research, given that there are five professors and 30 Ph.D. scholars who were using Drosophila to answer questions in developmental biology.

A total 57 talks and 240 posters on topics ranging from gametogenesis and stem cells, morphogenesis and mechanobiology, hormones and physiology, cellular and behavioural neurobiology, infection and immunity and ecology and evolution are scheduled for the conference.

One of the highlights of this conference is that we are explicitly encouraging undergraduates from various institutes of the world to participate in it. There is a pre-conference symposium called signals from the gut in collaboration with the National Centre for Cell Science, as well as a pre-conference microscopy workshop on super-resolution microscopy. This will feature microscopes from fluorescence imaging to super resolution imaging (50 nm resolution) which are vital for certain kinds of fly work, Prof. Dey said.

The last four editions of this conference took place in Taipei, Seoul, Beijing and Osaka.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Read the original here:
Pune to host fifth edition of global Drosophila conference - The Hindu